The muscle argument has been running for three years, mostly as a rhetorical weapon. Critics use lean mass loss to suggest these drugs are secretly harmful; advocates wave it away as a myth. Neither position survives contact with the data.
The pharmaceutical industry has now responded in the way it responds to everything, which is with another drug.
The problem being addressed
Lean mass accounts for a meaningful share of total weight lost on these drugs — commonly cited around a quarter, varying by trial, population and imaging method. This is not specific to GLP-1s; it happens with dieting and with bariatric surgery in similar proportions.
For a 35-year-old losing 15 percent of body weight, it is generally not clinically significant. For a 74-year-old with existing sarcopenia losing the same proportion, it can be.
~25%
Typical share of weight loss that is lean mass, across interventions
Myostatin
The signalling pathway most of these agents target
Function
The outcome that matters, and the one least often measured
How the drugs are supposed to work
Myostatin and activin are the body’s brakes on muscle growth. Block them and muscle mass increases — an effect known for decades and pursued repeatedly in muscular dystrophy and sarcopenia, with a long history of disappointment.
The GLP-1 era gives the idea a new and commercially attractive context: pair a highly effective fat-loss drug with an agent that keeps the lean tissue, and you get a better quality of weight loss rather than simply more of it.
The questions worth asking
Is it muscle that works? Mass and function have come apart before in exactly this drug class. Grip strength, gait speed and chair-stand tests are the endpoints to look for.
Who is it for? The clearest case is older adults and people with existing sarcopenia. Whether a healthy 40-year-old needs a second injectable to accompany the first is a different question, and it will not be the one the marketing addresses.
What does it cost? Two biologics instead of one, in a country where one is already unaffordable for a large share of the people who need it.
What is the alternative that already exists? Resistance training. Free, effective, evidenced, and available this afternoon.
There is something very characteristic about responding to the side effect of a drug with a second drug, when the intervention with the strongest evidence has been available for as long as heavy objects have.
What this does not change
If you are on a GLP-1 now, nothing about your plan should shift because of trials in progress.
The evidence-based response to lean mass loss remains the same three things: resistance training twice a week, adequate protein, and a rate of loss that is not maximal. Those work, they are available, and they have effects on strength, bone density, insulin sensitivity and mood that no antibody has demonstrated.
Whether you are actually doing them is a question worth answering with a record rather than an impression — most people overestimate both their protein intake and their training consistency by a wide margin, and a fortnight of honest logging in Zenday or anything similar settles it.
The version of this I would like to see
A trial that enrols the people who actually need it — older adults with low baseline muscle mass — measures whether they can stand up from a chair unaided at two years, and compares the drug against supervised resistance training rather than against nothing.
That trial would be genuinely useful and is unlikely to be run, because its most probable finding is that the free intervention works about as well.